<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366494</url>
  </required_header>
  <id_info>
    <org_study_id>23842</org_study_id>
    <nct_id>NCT02366494</nct_id>
  </id_info>
  <brief_title>Micro RNAs to Predict Response to Androgen Deprivation Therapy</brief_title>
  <official_title>Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify exosomal micro RNA that predict responses to ADT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Identify novel exosomal RNA signatures at pretreatment that predict response to ADT.&#xD;
&#xD;
           The study team will collect blood samples from patients with systemic disease&#xD;
           pretreatment (at enrollment), three months post-treatment and at the time of progression&#xD;
           of disease (or at two years post-ADT for patients still in remission at that time point)&#xD;
           and then perform next-generation sequencing using serum exosomal RNAs derived from these&#xD;
           patients.&#xD;
&#xD;
           The investigators plan to identify exosomal RNAs signatures that change between&#xD;
           pretreatment (at enrollment) and during treatment (at three months) and further explore&#xD;
           the effect of these changes on disease response. The investigators also plan to compare&#xD;
           exosomal RNA levels between patients relapse within the first two years versus those in&#xD;
           remission at two years. Among patients with progression, the investigators plan to&#xD;
           compare exosomal RNA signatures at progression of disease to signatures at pretreatment&#xD;
           and during treatment.&#xD;
&#xD;
        2. Validate exosomal RNA markers that predict response to ADT by real-time RT-PCR.&#xD;
&#xD;
      Secondary objectives: Selected RNAs, identified through the above process will be validated&#xD;
      using real-time RT-PCR assay to test reproducibility of RNA sequencing results. The&#xD;
      investigators expect to select and validate approximate five RNA markers that predict&#xD;
      duration of response to ADT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 29, 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify five most prevalent exosomal microRNAs that predict response to androgen deprivation therapy based treatment.</measure>
    <time_frame>Up to two years</time_frame>
    <description>Two hundred to 300 microRNAs will be identified by RNA sequencing. This outcome measure will report the read count per million of the top-five most prevalent microRNAs that correlate with responses.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Androgen blockade</arm_group_label>
    <description>Androgen DeprivationTherapy or Complete Androgen Blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <description>Hormonal therapy, novel oral hormonal therapy (abiraterone/apalutamide/enzalutamide) and chemotherapy (docetaxel)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>ANDROGEN BLOCKADE</description>
    <arm_group_label>Androgen blockade</arm_group_label>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>ANDROGEN BLOCKADE</description>
    <arm_group_label>Androgen blockade</arm_group_label>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>ANDROGEN BLOCKADE</description>
    <arm_group_label>Androgen blockade</arm_group_label>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>ANDROGEN BLOCKADE</description>
    <arm_group_label>Androgen blockade</arm_group_label>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Trelstar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Chemo hormonal therapy</description>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Chemo hormonal therapy</description>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Nonsteroidal antiandrogen medication</description>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Erleada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Nonsteroidal antiandrogen medication</description>
    <arm_group_label>Hormonal Therapy and Chemotherapy</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood collection at pre treatment (at enrollment), 3 months post treatment, and at the&#xD;
      time of disease progression (or at 2 years post treatment).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men with systemic disease ( with biochemical relpase or metastaic disease)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven prostate cancer.&#xD;
&#xD;
          -  Testosterone level &gt;30ng/ml and at least 6 months since last dose of hormonal therapy.&#xD;
&#xD;
          -  History/physical examination including a detailed description of the stage of prostate&#xD;
             cancer within 8 weeks prior to registration.&#xD;
&#xD;
          -  CT scan of abdomen and pelvis with IV contrast and bone scan should be performed&#xD;
             within 8 weeks prior to registration.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.&#xD;
&#xD;
          -  Age â‰¥ 18.&#xD;
&#xD;
          -  Patients must provide study-specific informed consent prior to study entry for this&#xD;
             project and mandatory blood specimen for banking for future studies (future studies&#xD;
             may include genetic testing).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received hormonal therapy less than 6 months prior to registration.&#xD;
&#xD;
          -  History of active secondary malignancy.&#xD;
&#xD;
          -  Decline hormone therapy for prostate cancer.&#xD;
&#xD;
          -  Current or previous treatment with 5-alpha reductase inhibitors within 6 months prior&#xD;
             to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak Kilari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006 Dec 1;24(34):5408-13.</citation>
    <PMID>17135641</PMID>
  </reference>
  <results_reference>
    <citation>Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.</citation>
    <PMID>18309951</PMID>
  </results_reference>
  <results_reference>
    <citation>Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40.</citation>
    <PMID>4625049</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Deepak Kilari</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>treatment response</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

